NCT00969033终止2 期
A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 9
- 主要终点
- Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone.
研究概览
简要总结
The purpose of this study is to determine the effect of CS-1008 in combination with irinotecan compared to irinotecan alone on Progression-Free Survival (PFS) in subjects with metastatic or advanced colorectal cancer (CRC) who have failed oxaliplatin-based first-line treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed CRC which is now metastatic and after failure of oxaliplatin-based first-line treatment.
- •At least 18 years of age.
- •ECOG performance status =<
- •Measurable disease based on RECIST criteria.
- •Adequate organ and bone marrow function as evidenced by:
- •Hemoglobin >= 9.0 g/dL (may be transfused to this level)
- •Absolute neutrophil count (ANC) >= 1.5 x 109/L
- •Platelet count >= 100 x 109/L
- •Serum creatinine =< upper limit of normal (ULN) or creatinine clearance > 50 mL/min
- •AST <= 2.5 x ULN in subjects with no liver metastasis and <= 5.0 x ULN in subjects with liver metastasis
- •Total bilirubin < 1.5 x ULN
- •Men and women of childbearing potential must be willing to consent to using effective contraception (e.g., hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for 3 months thereafter.
- •All female subjects of childbearing potential must have a negative pregnancy test (serum or urine) result within 7 days before initiating study treatment.
- •Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IEC/IRB approved ICF before performance of any study specific procedures or tests.
- •Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Anticipation of need for a major surgical procedure or radiotherapy (RT) during the study.
- •Treatment with chemotherapy hormonal therapy, RT, minor surgery, or any investigational agent within 4 weeks before study enrollment. Treatment with nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery within six weeks prior to study enrollment. St John's Wort within 2 weeks prior to study enrollment or during the study.
- •History of any of the following conditions within 6 months before study enrollment:
- •Clinically significant myocardial infarction or severe/unstable angina pectoris
- •New York Heart Association (NYHA) class III or IV congestive heart failure (Section 17.2)
- •Clinically significant cerebrovascular accident, transient ischemic attack or pulmonary embolism- Clinically significant pulmonary disease (e.g., severe chronic obstructive pulmonary disease or asthma)
- •Presence of any of the following: Symptomatic brain metastasis; an uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.
- •Clinically significant active infection that requires antibiotic therapy or Human Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy.
- •History of malignancy other than CRC, unless there is the expectation that the malignancy has been cured, and tumor specific treatment for the malignancy has not been administered within the previous 5 years. Exceptions to this are non melanotic cancer of the skin and adequately treated carcinoma of the cervix-in-situ.
- •Previous treatment with CS 1008, other agonistic DR5 antibody agents, or TRAIL agents.
- •History of active chronic inflammatory bowel disease and/or bowel obstruction within the last 3 months.
- •Pregnant or breast feeding.
- •Known history of hypersensitivity reactions to irinotecan or to one of the excipients.
研究组 & 干预措施
CS-1008 with irinotecan
Experimental
CS-1008 and irinotecan
干预措施: CS-1008 (Drug)
CS-1008 with irinotecan
Experimental
CS-1008 and irinotecan
干预措施: irinotecan (Drug)
irintoecan
Active Comparator
irinotecan alone
干预措施: irinotecan (Drug)
结局指标
主要结局
Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone.
时间窗: 1 year
次要结局
- Determine the difference in overall survival for CS-1008 administered in combination with irinotecan and irinotecan alone.(1 year)
- Determine the difference in median survival for CS-1008 administered in combination with irinotecan and irinotecan alone.(1 year)
- Determine the difference in objective response rate (ORR) for CS-1008 administered in combination with irinotecan and irinotecan alone.(1 year)
- To determine the Incidence of anti- CS-1008 antibody formation.(1 year)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver CancerAdvanced Hepatocellular CarcinomaHepatic CancerLiver NeoplasmsLiver CancerNCT01033240Daiichi Sankyo172
终止
2 期
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal CancerColorectal CancerNCT01060423Hans-Joachim Schmoll, MD8
已完成
2 期
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)Systemic Lupus ErythematosusNCT02885610RemeGen Co., Ltd.249
已完成
2 期
Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic CancerPancreatic CancerNCT00521404Daiichi Sankyo65
已完成
2 期
Combination Chemotherapy With CS-1008 to Treat Ovarian CancerOvarian Cancer Stage IIICOvarian Cancer Stage IVNCT00945191Daiichi Sankyo24